AiCure and The IMA Group Partner to Optimize Clinical Trial Recruitment and Patient Engagement
IMA Clinical Research, a division of The IMA Group, will equip patients with AiCure’s patient engagement solution to observe health management in a non-trial setting, advancing future trial recruitment criteria.
NEW YORK, March 15, 2021 — AiCure, an AI and data analytics company focused on improving clinical trials, and IMA, a national leader in providing clinical evaluation and research services, today announced a partnership to gain a widespread understanding of patient behavior and drug compliance outside of a clinical trial setting. With a database of over 300,000 potential subjects, IMA will roll out AiCure’s patient engagement solution, Patient Connect, to study participants, offering patients convenient and enhanced support to successfully manage their existing treatment at home.
The IMA Group Acquires EVOnational, an IME Services Provider
Latest acquisition adds 7,000 providers to IMA’s network and further expands its scope
Tarrytown, NY – February 23, 2021– The IMA Group (IMA) announced today it has acquired EVOnational, a national provider of independent medical exams (IMEs), medical screenings and other evaluations. The acquisition extends IMA’s scope and capabilities while enhancing its national offering of behavioral and medical evaluations. The company serves the workers’ compensation, liability, disability and auto markets.
Financial terms of the acquisition for the two privately held companies were not disclosed. To ensure a seamless transition for existing clients, EVOnational will continue to operate under its current name, with key leadership, processes and staff remaining in place.
“EVOnational brings our company the services, programs and people to ideally enhance and complement what we already offer our clients,” said IMA’s President Mark Weinberger, Ph.D., MPH. “Their experience and commitment to their clients, emphasis on technology designed for our industry and excellent provider panel give us the ability to help clients tackle the tough challenges facing the industry today.”
Beyond Diversity: IMA Clinical Research Taps into Underserved Patient Populations
The FDA has issued guidance that promotes the inclusion of diverse populations in clinical trials to better understand the risk and benefits across all groups. The traits of these groups can include gender, race, ethnicity, age and location of residency. With today’s focus on the topic, Dr. Howard Chipman, Principal Investigator, IMA Clinical Research, shares his insights, focusing on the importance of geographic footprints, as well as factors some may not consider, such as non-demographic traits.
Dr. Mario Rocci Joins The IMA Group as Strategic Advisor in Clinical Research
Industry veteran to expand company’s Clinical Research Division
Tarrytown, NY – January 12, 2021 – Mario Rocci, PhD, FCP, FFIP, a seasoned executive with 35 years of scientific and business management experience, has joined The IMA Group (IMA) as Strategic Advisor in the Clinical Research division.
IMA Clinical Research is a network of integrated research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA performs trials with a flexible model using both their physical locations and virtual capabilities that reach people around the country to support the advancement of safe and effective medication therapies. Additionally, IMA also maintains a robust study participant database to recruit and complete trials efficiently.
“Given the current international attention on clinical trials stemming from the COVID-19 pandemic, there is an increasing emphasis for quality, reputable research that can be delivered quickly,” said Mark Weinberger, PhD, MPH, President of IMA. “Mario shares our excitement for the growth of IMA through its unique network of sites and infrastructure. His extensive background in pharma, both in academia and industry, will greatly enhance IMA’s leadership team with greater visibility and standing in the field.”
The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19.
The IMA Group will be partnering with SUNY Schenectady to bring the latest testing technology and methodologies to battle COVID-19. The individual saliva swab diagnostic test, developed by SUNY Upstate Medical University and Quadrant Biosciences, recently received emergency approval by the FDA. The new test, will be used with Upstate Medical’s and Quadrant’s innovative pool testing, which allows for 10 to 25 people to be screened in one COVID-19 test.
The IMA Group partners with Rensselaer County on COVID-19 testing for students
We are very proud to partner with Rensselaer County to provide two dedicated days of COVID-19 testing for college students.
Clinical Research Studies During the COVID-19 Pandemic Public Health Emergency
Jennifer Goldfarb, MSN, RN, CCRP, VP of IMA’s Clinical Research, recently wrote an article for the Society of Clinical Research Associates (SOCRA) entitled Defining a “New Normal” in Clinical Research to Support the World’s 336,747 Research Studies
New York’s The IMA Group Hires Markham as Chief Strategy Officer
May 12, 2020 – The IMA Group has hired Doug Markham, a healthcare and managed care industry veteran with more than 25 years of experience, as chief strategy officer.
Markham has a background in healthcare, insurance, claims and managed care services. Prior to joining IMA, he held executive leadership positions with a number of organizations, including York Risk Services, CareWorks Managed Care Services and Concentra.
Industry Veteran Doug Markham Joins The IMA Group as Chief Strategy Officer
TARRYTOWN, N.Y. — May 12, 2020 – Doug Markham, a healthcare and managed care industry veteran with more than 25 years’ experience, has joined The IMA Group (IMA) as Chief Strategy Officer. IMA is one of the nation’s leading providers of medical and psychological evaluations, as well as clinical research, working with employers, insurance carriers, TPAs and government agencies nationwide.
“One of the most important things we can do as an organization is to help people get back to productivity and their daily lives,” said Mark Weinberger, PhD, MPH, President of IMA. “Doug shares our passion and commitment. His leadership and experience will help our company continue to grow and meet the needs of our constituents.”
In Response To COVID-19 Pandemic PsyBar Expands Its HIPAA-Compliant, IME, Pre-Employment & Fitness For Duty Teleassessment Exam Services
MINNEAPOLIS, MN – May 5, 2020 — PsyBar, a division of The IMA Group and one of the nation’s leading specialty providers of disability, workers’ compensation and other employment-related behavioral health forensic evaluations, has responded to the country’s need to address mental health issues related to the nation’s shutdown as a result of the COVID-19 pandemic by expanding its teleassessment services.
Urgently-needed behavioral health forensic pre-employment, independent medical exams (IMEs) and fitness for duty exam (FFDE) evaluations can now be provided via a secure, online platform.
Rensselaer County announces COVID-19 testing sites
RENSSELAER COUNTY, N.Y. — The county is partnering with Whitney Young and IMA Group with LabCorp to have testing sites next week.
According to Rensselaer County Executive Steve McLaughlin, Whitney Young will set up mobile testing sites in the city of Troy and the city of Rensselaer beginning next week.
The testing with IMA Group and Lab Corp is expected to start next week and will be conducted at Hudson Valley Community College.
The IMA Group Announces Acquisition of PsyBar, Expands Footprint as Single Source Provider
Company now offers network of national, board-certified psychologists, neuropsychologists and psychiatrists for range of IME, pre-employment, Fitness for Duty and disability screenings, as well as other services
Tarrytown, NY – February 26, 2020 – Recognizing the growing importance of quality behavioral health programs for payers, The IMA Group (IMA) announced today the acquisition of PsyBar, one of the nation’s leading specialty providers of behavioral health, independent medical exams (IME), and other employment related services.
Financial terms of the acquisition were not disclosed. To ensure a seamless transition for existing clients, PsyBar will continue to operate under its current name, with all key leadership remaining in place.